G ene therapy represents a powerful weapon in the battle against cancer. By genetically altering tumor cells, we can elicit profound changes within the tumor microenvironment, allowing the host to reject the malignancy. Several promising genetic approaches for tumor therapy have been developed including: (a) modification of tumor cells with cytokine genes to enhance their immunogenicity, (b) transfer of tumor-suppressor genes into malignant cells to reduce their tumorigenicity, and (c) introduction of "suicide genes" into cancer cells that convert nontoxic prodrugs to toxic anti-metabolites. In all cases, there is evidence that the innate immune system plays an important role in the antitumoral activity. [1] [2] [3] [4] [5] Therefore, it would be advantageous to use a gene delivery vehicle that can activate innate immunity and enhance these cancer gene therapy strategies.
Direct injection of DNA complexed to cationic liposomes (lipoplexes) into growing tumor nodules has been used successfully in murine tumor models, and these strategies have already been extended into phase I clinical trials. There is growing evidence from murine studies that direct administration of lipoplexes into established tumors could inhibit growth in the absence of a therapeutic transgene (Refs. 1, 6, and 7; R.W.G., unpublished observations). This antitumoral activity may be related to lipoplex-induced inflammation, as previous reports have described an inflammatory response that occurs after lipoplex administration to the lung. 8, 9 However, it was not clear from those studies whether this response is general for all cationic lipids or how the inflammation may impact the antitumoral effector mechanisms of the host. These results are further confounded by a recent observation that intraperitoneal (i.p.) injection of cationic liposomes can suppress inflammation in experimental mouse models. 10 The studies described herein compared the transfection and inflammatory profiles of three different cationic lipoplex formulations containing N,N-dioleyl-N,N-dimethylammonium chloride (DODAC), N-(1- [2,3-dioleoyloxy] propyl)-N,N,N-trimethylammonium chloride (DOTAP), or N- (1-[2,3-dioleyloxy] propyl)-N,N,N-trimethylammonium chloride (DOTMA). We determined that all three formulations produce inflammation after i.p. administration, although the duration and magnitude of the response generated using the DODAC and DOTMA lipoplexes was greater than the response generated using DOTAP lipoplexes. The lipoplex-induced inflammation was associated with a local increase in interferon-␥ (IFN-␥) expression and natural killer (NK) activity, indicating a role for lipoplexes as adjuvants for tumor gene therapies.
MATERIALS AND METHODS

Cell culture
MCA207 (murine fibrosarcoma), SKOV-3 (human ovarian carcinoma; HTB-77, American Type Culture Collection (ATCC), Manassas, Va), LS180 (human colorectal carcinoma), and WEHI 13VAR (CRL-2148, ATCC) were cultured in cRPMI (RPMI 1640, 10% fetal calf serum, 50 M 2-mercaptoethanol, 2 mM L-glutamine, 100 U/mL streptomycin, and 100 g/mL penicillin). All tissue culture medium reagents were purchased from Life Technologies (Gaithersburg, Md); Falcon plasticware was purchased from Becton Dickinson (Franklin Lakes, NJ).
Reagents
Supercoiled plasmid DNA was purified using a modified alkaline lysis procedure followed by purification using a CsCl/ EtBr gradient. 11 The luciferase expression plasmid, pCMVluc18, has been described previously.
12 DODAC and DOTMA were prepared by Dr. Steven Ansell (Inex Pharmaceuticals, Vancouver, British Columbia, Canada). DOTAP and DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine) were obtained from Avanti Polar Lipids (Alabaster, Ala). Actinomycin D and N- (1-napthyl) ethylenediamine, sulfanilamide were purchased from Sigma (St. Louis, Mo).
Preparation of large unilamellar vesicles (LUVs)
Lipid films were prepared by lyophilization of lipid solutions composed of 10 mg/mL lipid in 100% ethanol. The lipids were resuspended in water at a final concentration of 40 mM lipid. The solubilized liposomes were then extruded 10 times through a 100-nm carbonate membrane to generate LUVs and stored at 4°C. The LUVs used in these studies were composed of a 1:1 molar ratio of cationic lipid (DODAC, DOTMA, or DOTAP) and DOPE.
Lipoplex formation
LUV/DNA complexes were prepared at a charge ratio of ϩ3. A solution was prepared containing pCMVluc18 at a final concentration of 500 g/mL in 5% glucose. The DNA solution was added dropwise to a solution containing 9.0 mM DODAC: DOPE (1:1) LUVs in 5% glucose while vortexing. The complexes were then incubated for 30 minutes at 4°C. Lipoplexes were prepared fresh before each use.
Luciferase and protein assays
Luciferase assays were performed using the Luciferase Assay System kit (Promega, Madison, Wis) as described previously. 12 Cellular lysates were assayed for protein content using the bicinchoninic acid colorimetric method (Pierce, Rockford, Ill) according to the manufacturer's protocol.
Murine peritonitis
Female C57BL/6 mice (Harlan Sprague-Dawley, Indianapolis, Ind) received an i.p. injection of LUVs or lipoplexes in 200 L of 5% glucose (lipid dose ϭ 60 mg/kg). At specified timepoints, the mice were euthanized by asphyxiation with CO 2 and peritoneal exudate cells were recovered by lavage with 5 mL of ice-cold Hanks' balanced salt solution. The concentration of cells in the lavage was quantified using a cell counter (Coulter Diagnostics, Hialeah, Fla), and the cells were washed twice with Hanks' balanced salt solution. After the final wash, the cell pellet was resuspended in cRPMI.
NK assay
To measure NK activity, peritoneal exudate cells were tested for their ability to lyse 51 Cr-labeled YAC-1 cells as described by Bramson et al. 13 One lytic unit (LU) is equal to the number of exudate cells required to produce 30% specific lysis of 5000 YAC-1 cells.
Tumor necrosis factor-␣ (TNF-␣) bioassay TNF-␣ bioassay was carried out as described by Khabar et al 14 with the following modification: At the end of the assay period, 100 L of supernatant was removed from each well, 20 L of MTS solution (CellTiter 96 Aqueous Nonradioactive Cell Proliferation Assay, Promega) was added to each well, and the plates were incubated for an additional 1.5 hours. The absorbance of the solution in each well was measured at 490 nm. The concentration of TNF-␣ in the experimental wells was calculated by comparison with recombinant standards. Routinely, this assay was sensitive to 15 pg/mL recombinant standard.
Cytokine enzyme-linked immunosorbent assays (ELISAs)
IFN-␥ (Endogen, Woburn, Mass) and interleukin-12 (IL-12) p70 (PharMingen, San Diego, Calif) levels were measured using a specific ELISA as described by the manufacturer.
Nitric oxide (NO) release assay
Aliquots of 5 ϫ 10 5 peritoneal exudate cells were transferred to 24-well plates. The cells were then incubated for 24 hours in medium Ϯ 10 ng/mL lipopolysaccharide (LPS) in a total volume of 1 mL. After the incubation period, the concentration of nitrates in the supernatant was determined using the Griess assay. A 100-L aliquot of the culture medium was mixed with 100 L of Griess reagent (equal volumes of Griess reagent A (0.1% N-(1-napthyl)ethylenediamine) and Griess reagent B (1% sulfanilamide in 5% phosphoric acid)) in a flat-bottom 96-well plate. The absorbance of each well was then measured at 570 nm. Nitrate concentration was determined using a standard curve ranging from 1 mM to 1.6 M.
RESULTS AND DISCUSSION
Transfection profile of DODAC, DOTMA, and DOTAP LUVs, prepared using equimolar concentrations of cationic lipid and DOPE, were complexed with plasmid DNA to generate lipoplexes as described in Materials and Methods. It has been determined that cationic lipid:DNA (ϩ:Ϫ) charge ratios of ϩ3 or greater generate lipoplexes with highly efficient transfection profiles in vitro (our unpublished results). Routinely, we use lipoplexes prepared with a charge ratio of ϩ3, as these complexes exhibit excellent transfection with minimum lipid-associated toxicity. Similarly, Yang and Huang 15 demonstrated that the serum instability of DOTAP: DOPE lipoplexes can be overcome when charge ratios of greater than ϩ3 are used. The lipoplexes used in all of the following studies were prepared using the plasmid pCMVluc18 and either DODAC:DOPE, DOTAP: DOPE, or DOTMA:DOPE LUVs. The transfection efficiency was determined using three cell lines (MCA207, SKOV-3, and LS180; Fig 1) . The DODAC lipoplexes yielded similar levels of transfection on all three cell lines (luciferase expression at 24 hours ϭ 559 Ϯ 39 pg/well on MCA207 cells, 1042 Ϯ 34 pg/well on SKOV-3 cells, and 671 Ϯ 53 pg/well on LS180 cells) (Fig 1A) . DOTMA lipoplexes were similar in efficiency to DODAC lipoplexes on MCA207 and LS180 cells (303 Ϯ 24 pg/well and 605 Ϯ 35 pg/well, respectively) but were not very efficient on SKOV-3 cells (21 Ϯ 3 pg/well) (Fig 1B) . DOTAP:DOPE had the weakest transfection profile, with luciferase expression of 12 Ϯ 1 pg/well on SKOV-3 cells, 145 Ϯ 25 pg/well on MCA207 cells, and 157 Ϯ 47 pg/well on LS180 cells (Fig 1C) . The protein contents of the various lysates were measured and found to be the same among the three sets of transfections, indicating that the difference in transfection efficiency between the various formulations was not due to differences in toxicity (data not shown).
Lipoplex-induced peritonitis as a quantitative measure of inflammation Histological analysis of tissue sites (muscle and footpad) after lipoplex delivery in vivo revealed a robust inflammatory response (Branson J, Graham R, unpublished data). Unfortunately, it was quite difficult to quantify the inflammatory response histologically. Other groups have described the inflammation after intratracheal (i.t.) administration of lipoplexes by measuring cellular infiltrate and cytokine secretion in the bronchoalveolar lavage (BAL). 8, 9 However, i.t. instillation reflects events that occur at mucosal surfaces and may not accurately reflect the host response after subcutaneous or i.p. injection of lipoplexes. To provide a quantitative measure of the inflammatory response after parenteral administration, we have developed a model of lipoplex-induced peritonitis. Various formulations were injected into the peritoneum of wild-type C57BL/6 mice, and the peritoneal exudate was harvested at various timepoints over a period of 5 days. The exudate was then analyzed for a number of indicators of inflammation: cellular infiltrate, cytokine release, and NK activation.
Cellular infiltrate after lipoplex administration to the peritoneal cavity
The number of infiltrating cells within the peritoneal lavage samples increased steadily over a 5-day period after the administration of DODAC-or DOTMA-containing lipoplexes (Fig 2) . The mean number of cells in the peritoneal exudate after delivery of DODAC-containing lipoplexes was 20.3 ϫ 10 6 cells/mouse and 35.4 ϫ 10 6 cells/mouse at days 3 and 5, respectively, compared with 5.4 ϫ 10 6 cells in the lavage of a mouse at day 0 (Fig 2, Ⅺ) . The infiltrate was even greater after administration of DOTMA-containing lipoplexes, reaching 30.4 ϫ 10 6 cells/mouse and 40.6 ϫ 10 6 cells/mouse at days 3 and 5, respectively (Fig 2, E) . Interestingly, the cellular infiltrate that developed after the administration of DOTAP-containing lipoplexes reached levels that were similar to those seen for DOTMA lipoplexes at day 3 (mean cellular infiltrate ϭ 30.8 ϫ 10 6 cells/mouse) and resolved to near normal levels by day 5 (mean cellular infiltrate ϭ 12.3 ϫ 10 6 cells/mouse) (Fig 2, छ) .
Cytokines released into the peritoneal exudate
The proinflammatory cytokines TNF-␣, IFN-␥, and IL-12 have been studied extensively with respect to their antitumoral activities. These cytokines have potent immunostimulatory properties, can activate NK cells and macrophages, and can prime cytotoxic T lymphocytes for enhanced cytolytic activity. In addition, TNF-␣ and IFN-␥ can be directly cytotoxic to tumor cells. The presence of such cytokines within the microenvironment of the tumor can enhance local immunity and promote tumor rejection. 16 The peritoneal lavage samples were tested for TNF-␣ using a bioassay, and IFN-␥ and IL-12 p70 levels were measured by ELISA. TNF-␣ and IL-12 p70 were not detectable at day 1, day 3, or day 5 after lipoplex administration in any of our lavage samples. IFN-␥, however, was readily measurable within the lavage samples of animals treated with all three cationic lipids (Fig 3) . At 24 hours postadministration, the IFN-␥ levels within the lavage samples from mice treated with DODAC, DOTAP, and DOTMA were 420 Ϯ 160, 356 Ϯ 154, and 270 Ϯ 74 pg/mL, respectively. As we observed with the cellular infiltrate, the IFN-␥ response resolved more rapidly in the animals treated with DOTAP lipoplexes than in animals treated with either DODAC or DOTMA lipoplexes. By 72 hours postinjection, no IFN-␥ was detectable within the peritoneal exudate from mice treated with DOTAP lipoplexes, but levels of IFN-␥ within the peritoneum of mice treated with DODAC and DOTMA lipoplexes were higher than at 24 hours (482 Ϯ 140 and 512 Ϯ 134 pg/mL, respectively). The levels of IFN-␥ diminished by day 5 (92 Ϯ 21 and 76 Ϯ 26 pg/mL after DODAC lipoplex and DOTMA lipoplex treatment, respectively). The presence of IFN-␥ within the microenvironment after lipoplex administration can be directly cytotoxic to tumor cells and should provide adjuvant stimulus to cancer gene therapy by activating antitumor T cells and local macrophages.
It is not clear why we were unable to detect TNF-␣ or IL-12 p70. The kinetics of TNF-␣ release in the sera after i.p. administration of LPS peaked at 1.5 hours and were almost undetectable at 24 hours. 17 Similarly, TNF-␣ was readily detectable (ϳ50 ng/mL) in the BAL at 2 hours after i.t. lipoplex administration, but was almost undetectable in BAL samples (Ͻ10 pg/mL, below the lower limit of the TNF-␣ bioassay used in our study) taken 24 hours after lipoplex administration. 9 Therefore, although it is quite possible that TNF-␣ was produced at early timepoints after i.p. lipoplex administration, it is not surprising that it was not detected at 24, 72, and 120 hours postinjection. However, the lack of IL-12 within the peritoneal lavage is surprising, particularly because the expression of IFN-␥ was substantially increased. Blezinger et al 7 also observed increased IFN-␥ levels in BAL samples from mice treated i.t. with lipoplexes in the absence of obvious IL-12 secretion. One explanation is that the IFN-␥ secretion (which peaks at day 3 in the DODAC and DOTMA samples) is not induced via the IL-12 pathway. A recently described cytokine, IFN-␥-inducing factor/IL-18, can promote IFN-␥ expression and NK cell activation independently of IL-12. 18 Another possibility is that the IFN-␥ may be secreted into the peritoneal fluids by infiltrating immunocytes that were activated by IL-12 at a site outside the peritoneal cavity.
Increased NK activity in the peritoneal lavage The major sources of IFN-␥ at early times in inflammatory reactions are NK and NKT cells. 19 Because IFN-␥ secretion is generally correlated with activation of the effector cells, we measured the cytolytic activity of the peritoneal exudate cells on the NK/NKT-sensitive target YAC-1 (Fig 4) . The activity is reported in terms of LU to allow a quantitative comparison of the various treatments. NK activity was present in all treated lavages over the 5-day experimental period. No NK activity was detectable within the peritoneum of control mice. The increase in lytic activity paralleled the accumulation of cellular infiltrate. The DODAC and DOTMA lipoplexes elicited a progressive increase in NK activity over a period of 5 days, whereas the DOTAP lipoplexes induced NK activity that peaked at day 3 but remained substantially elevated at day 5 (Fig 4) . As with IFN-␥ release, the level of NK activity at 24 hours was similar in all treated groups (36.7 Ϯ 12.0 LU, 32.4 Ϯ 7.0 LU, and 71.3 Ϯ 29.0 LU after treatment with DODAC, DOTAP, and DOTMA lipoplexes, respectively). At 72 hours, the activity within the lavages from animals treated with DOTAP lipoplexes peaked at 552.2 Ϯ 96.0 LU. At the same time, NK activities within the peritoneum of DODAC-and DOTMA-treated animals were substantially lower (199.0 Ϯ 53.0 and 225.9 Ϯ 77.0, respectively). As with the cellular infiltrate, the day 5 peritoneal NK activity in the DOTAP lipoplex-treated animals had abated (139.0 Ϯ 29.0 LU), whereas the activity in the lavage samples from DODAC-and DOTMA-treated animals continued to rise (253.0 Ϯ 27.0 LU and 431.0 Ϯ 123.0 LU, respectively).
We have also determined that there was an increase in activated macrophages within the peritoneal cavity over the course of the inflammatory response. Peritoneal exudate cells from all treated groups were stimulated in vitro using a suboptimal dose of LPS (10 ng/mL). The level of NO within the culture supernatant was measured 24 hours later. Peritoneal exudate cells from control mice did not release detectable NO under these conditions. The increase in NO released by exudate cells obtained from lipoplex-treated animals paralleled the increase in NK activity (Fig 5) . Thus, the inflammatory response to cationic lipoplexes results in the presence of increased antitumoral effector cells as measured by increased lytic activity against YAC-1 cells and the presence of activated macrophages that were hypersensitive to LPS stimulation.
Our results appear to contradict other experiments indicating that cationic lipids have anti-inflammatory activity. 10 Those studies demonstrated that parenteral treatment with a variety of structurally distinct cationic lipids could suppress the inflammation induced by a footpad injection of carageenan or sheep red blood cells in sensitized mice. In addition, i.p. administration of liposomes composed of a 1:1 mixture of DOTAP and DOPE suppressed carageenan-induced footpad swelling. In contrast, we have observed that LUVs alone, at the same dose as the aforementioned studies (60 mg/kg), induced peritoneal inflammation after i.p. administration, although the magnitude and duration of the inflammatory response were not as pronounced as the response after treatment with lipoplexes (data not shown). These observations may be reconciled by the fact that the former studies investigated the impact of parenteral administration of cationic lipids on inflammation induced by a different agent at a distant site (i.e., the footpad), whereas the studies described herein investigated the local effects (i.e., within the peritoneal cavity).
Interestingly, the inflammation induced by DOTAP lipoplexes resolved more quickly than the inflammation induced by DODAC and DOTMA lipoplexes. This may reflect differences in the physical structure of the three cationic lipids. Filion and Phillips 10 have demonstrated that DOTAP can suppress NO production and TNF-␣ secretion from activated macrophages. It was suggested that DOTAP may suppress activated macrophages by inhibiting protein kinase C. Because DOTAP has a glycerol backbone and is structurally similar to the natural ligand for protein kinase C, diacylglycerol, it may represent a more effective inhibitor of protein kinase C function than DOTMA or DODAC, thereby leading to a more rapid resolution of lipoplex-induced inflammation. Thus, although the lipoplexes themselves may induce inflammation, the cationic lipids that are freed after metabolism of the complexes may be able to suppress the inflammation. Alternatively, the lipoplexes generated by complexing DNA with DOTAP:DOPE liposomes may be structurally distinct from those generated by DNA complexed to DODAC:DOPE or DOTMA:DOPE liposomes. Lipoplex structure might determine the ability of these agents to transfect cells and activate inflammation. In any case, these observations are important in the design of in vivo gene therapies. The successful gene therapy will likely require a balance between inflammatory potential and transfection efficiency. If the two events are directly related, as these studies suggest, then the choice of cationic lipid used for lipoplex generation may have to be determined empirically and will likely be dependent upon the particular application.
The aim of these studies was to measure the immunological response to cationic lipoplexes in a quantitative manner. A number of physiological changes have been measured that could have significant impact on the outcome of tumor therapy. Previous reports have demonstrated that tumors secrete cytokines, such as IL-10 and transforming growth factor-␤, which can suppress dendritic cell function leading to immunological tolerance. 20 As inflammatory signals are required to achieve proper maturation and function of dendritic cells, the inflammatory response that follows lipoplex administration may reverse the effect of tumor-derived cytokines. The IFN-␥ secreted after exposure to lipoplex has multiple effects that can lead to tumor rejection. 21 This cytokine can be directly cytotoxic to tumor cells, can prime macrophages to enhance their tumoricidal activity, and can promote the maturation of cytotoxic T cells; in addition, it has been shown that IFN-␥ is critical for the antitumoral effects of IL-12. Finally, it was observed that lipoplex administration leads to increased local NK activity, which can be of therapeutic benefit clinically. 22 Thus, the combined effects of the response to lipoplex administration produce changes in the microenvironment that favor rejection of tumor cells by the host. These results can explain studies in which inhibition of tumor growth was observed after treatment with lipoplexes in the absence of a therapeutic transgene. 1, 6, 7 It is clear, however, that there are instances in which a therapeutic transgene is required to observe antitumoral activity. In at least three studies, growing tumors treated with cationic liposomes complexed to a plasmid encoding the therapeutic transgenes had a much greater response than the groups treated with either the therapeutic plasmid alone or cationic liposomes complexed to a control plasmid. 7, 23, 24 Transgene expression was not greatly enhanced by the cationic liposome formulations (Ͻ2-fold), so enhanced transfection would not explain the increased potency of the DNA/cationic liposome complex compared with naked DNA. In similar studies in which reporter genes were used, cationic lipids did not improve transgene expression after direct injection of plasmid DNA into muscle, brain, or tumor (our unpublished observations; Refs. [25] [26] [27] . Thus, the enhanced activity of lipoplexes compared with naked DNA in tumor therapies is likely to due to the adjuvant effect of the lipoplex. Consistent with this hypothesis, results from a recent clinical trial employing a plasmid encoding human histocompatibility leukocyte antigen-B7 complexed to Lipofectamine (DOSPA:DOPE (3:1)) demonstrated increased NK activity in the peripheral blood associated with response to treatment. 28 These results support further investigation of lipoplexes in cancer gene therapy and indicate a role for an adjuvant effect of the lipoplex leading to enhanced potency of DNA-based therapies.
